Vaccinia Virus—A Swiss Army Knife Against Cancer

TL;DR

This paper reviews how vaccinia virus can be used to kill cancer cells and boost the immune system's fight against cancer.

Contribution

The paper highlights vaccinia virus as a versatile and potent oncolytic agent with unique immune-evasion properties.

Findings

Vaccinia virus can directly kill tumor cells and activate T cells to fight cancer.

The virus's ability to evade immune defenses makes it a strong candidate for oncolytic therapy.

Ongoing research is exploring its use against various cancer types.

Abstract

This review explores the potential of the vaccinia virus (VACV) as a powerful tool in oncolytic cancer treatment. While current therapies often fall short for patients with advanced cancer, VACV offers a promising approach by directly killing tumor cells and activating the body’s immune system—particularly T cells—to fight cancer. The review highlights the virus’s unique ability to evade immune defenses, its interactions with the immune system, and ongoing research into its use as an oncolytic agent against various cancer types. Overall, VACV is presented as a versatile and impactful candidate for future cancer therapies.

Despite significant advances in cancer therapy, the prognosis for patients with advanced, disseminated disease remains poor. This underscores the urgent need for novel treatments that not only eliminate tumor cells effectively but also stimulate a strong, durable anti-cancer immune response. Among emerging strategies, oncolytic viruses have shown exceptional promise due to their selective cytotoxicity and their ability to activate T cell-mediated immune responses. In this review, we focus on the vaccinia virus (VACV), a member of the Poxviridae family, which has emerged as a leading candidate in modern oncolytic immunotherapy. We examine the virus’s properties that enable it to evade antiviral defenses and serve as a versatile, potent oncolytic agent. Furthermore, we explore its interactions with various components of the immune system and how these contribute to the induction of a robust T cell-driven response. Finally, we assess current efforts to harness VACV for the treatment of various cancer types and highlight future directions where its application is most likely to succeed. Overall, our goal is to present VACV as a powerful and broadly applicable platform with the potential to transform the landscape of oncology.

Figures